Zoresan Dosage/Direction for Use

Zonisamide (Zoresan) may be taken as monotherapy or added to existing therapy in adults. The dose should be titrated on the basis of clinical effect. Recommended escalation and maintenance doses are given in Table 2. Some patients, especially those not taking CYP3A4-inducing agents, may respond to lower doses.
Withdrawal: When Zonisamide (Zoresan) treatment is to be discontinued, it should be withdrawn gradually.
In clinical studies of adult patients, dose reductions of 100 mg at weekly intervals have been used with concurrent adjustment of other antiepileptic medicine doses (where necessary). (See Table 2.)

Click on icon to see table/diagram/image

General dosing recommendations for Zonisamide (Zoresan) in special patient populations: Paediatric population (aged 6 years and above): Dosage escalation and maintenance: Zonisamide (Zoresan) must be added to existing therapy for paediatric patients aged 6 years and above. The dose should be titrated on the basis of clinical effect. Recommended escalation and maintenance doses are given in Table 3. Some patients, especially those not taking CYP3A4-inducing agents, may respond to lower doses.
Physicians should draw the attention of paediatric patients and their parents/carers to the Patient Alert Box (in the package leaflet) on preventing heatstroke. (See Table 3.)

Click on icon to see table/diagram/image

The safety and efficacy of Zonisamide (Zoresan) in children aged below 6 years or those below 20 kg have not yet been established.
There are limited data from clinical studies in patients with a body weight of less than 20 kg. Therefore, children aged 6 years and above and with a body weight less than 20 kg should be treated with caution.
It is not always possible to precisely achieve the calculated dose with the commercially available capsule strengths of Zonisamide (Zoresan). In these cases it is therefore recommended that the Zonisamide (Zoresan) total dose should be rounded up or down to the nearest available dose that can be achieved with commercially available capsule strengths of Zonisamide (Zoresan) (25 mg, 50 mg and 100 mg).
Withdrawal: When Zonisamide (Zoresan) treatment is to be discontinued, it should be withdrawn gradually.
In clinical studies of paediatric patients, down-titration was completed by dose reductions at weekly intervals in increments of about 2 mg/kg (i.e. in accordance with the schedule in Table 4). (See Table 4.)

Click on icon to see table/diagram/image

Elderly: Caution should be exercised at initiation of treatment in elderly patients as there is limited information on the use of Zonisamide (Zoresan) in these patients. Prescribers should also take account of the safety profile of Zonisamide (Zoresan).
Patients with renal impairment: Caution must be exercised in treating patients with renal impairment, as there is limited information on use in such patients and a slower titration of Zonisamide (Zoresan) might be required. Since zonisamide and its metabolites are excreted renally, it should be discontinued in patients who develop acute renal failure or where a clinically significant sustained increase in serum creatinine is observed.
In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance. The plasma AUC of zonisamide was increased by 35% in subjects with creatinine clearance < 20 mL/min.
Patients with hepatic impairment: Use in patients with hepatic impairment has not been studied. Therefore, use in patients with severe hepatic impairment is not recommended. Caution must be exercised in treating patients with mild to moderate hepatic impairment, and a slower titration of Zonisamide (Zoresan) may be required.
Effect of food: Zonisamide (Zoresan) may be taken with or without food.
Mode of administration: Oral.